“Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma” has been added to your cart. View cart
Article: O.2 RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response
O.2 RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response
Reviews
There are no reviews yet.
Be the first to review “Article: O.2 RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response” Cancel reply
Reviews
There are no reviews yet.